GO:0097242 amyloid-beta clearance: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097242 amyloid-beta clearance describes the removal of amyloid-beta (Aβ) from extracellular brain regions via cell surface receptors.
• Impaired Aβ clearance, rather than overproduction alone, is a major driver of Aβ accumulation in Alzheimer's disease.
• Peripheral clearance by monocytes and other immune cells contributes significantly to Aβ removal from the brain.
• Key receptors and transporters involved include LRP1, RAGE, ABCA1, APOE, and TREM2, which mediate Aβ uptake and efflux.
• Therapeutic strategies targeting Aβ clearance include anti-Aβ antibodies such as plaque-specific antibodies that clear existing plaques.
• Research methods to study Aβ clearance include knockout and knock-in mouse models, cellular uptake assays, and CRISPR screens.
Description
Amyloid-beta clearance (GO:0097242) is a biological process defined as the removal of amyloid-beta (Aβ) from extracellular brain regions by mechanisms involving cell surface receptors. Aβ is a peptide derived from the amyloid precursor protein (APP) and is central to the amyloid hypothesis of Alzheimer's disease. The balance between Aβ production and clearance determines its accumulation in the brain, and impaired clearance is strongly implicated in Alzheimer's disease pathogenesis. This process is critical for maintaining brain homeostasis and preventing neurotoxicity. Researchers study amyloid-beta clearance to understand neurodegenerative disease mechanisms and to develop therapeutic interventions that enhance Aβ removal.
amyloid-beta clearance At A Glance
| GO ID | GO:0097242 |
|---|---|
| GO term | amyloid-beta clearance |
| Ontology | biological_process |
| Synonym | beta-amyloid clearance |
| Major function | Removal of amyloid-beta from extracellular brain regions via cell surface receptors |
| Related diseases | Alzheimer's disease, cerebral amyloid angiopathy |
| Key cell types | Neurons, microglia, astrocytes, monocytes |
| Subcellular location | Extracellular space, cell surface, endosomes |
What Is GO:0097242?
According to the Gene Ontology, amyloid-beta clearance (GO:0097242) is the process in which amyloid-beta is removed from extracellular brain regions by mechanisms involving cell surface receptors. This includes receptor-mediated uptake, transport across the blood-brain barrier, and enzymatic degradation, ultimately reducing Aβ burden in the brain.
Why Is amyloid-beta clearance Important in Cell Biology?
Amyloid-beta clearance is crucial because failure of this process leads to Aβ accumulation, a hallmark of Alzheimer's disease. Decreased clearance of CNS Aβ has been demonstrated in Alzheimer's disease patients, highlighting its central role in disease progression. Understanding the mechanisms of Aβ clearance can inform therapeutic strategies aimed at enhancing removal and preventing cognitive decline.
• Impaired Aβ clearance is a key mechanism in Alzheimer's disease pathogenesis.
• Peripheral clearance by monocytes contributes to Aβ removal and is a potential therapeutic target.
• Receptor-mediated transport across the blood-brain barrier regulates brain Aβ levels.
• Genetic variants in clearance-related genes (e.g., APOE, TREM2) increase Alzheimer's risk.
• Enhancing Aβ clearance with antibodies can reduce plaques in animal models.
• Aβ clearance dysfunction is linked to cerebral amyloid angiopathy and vascular cognitive impairment.
• Clearance mechanisms are being explored for therapeutic development in neurodegeneration.
• Studying Aβ clearance requires integrated approaches from molecular to systems levels.
What Happens During amyloid-beta clearance?
Receptor-Mediated Uptake
In simple terms: Cells use surface receptors to grab amyloid-beta and pull it inside.
Cell surface receptors such as LRP1, RAGE, and scavenger receptors bind Aβ and mediate its internalization into cells, including neurons, microglia, and endothelial cells. This uptake is a primary step in clearing Aβ from the extracellular space.
Transport Across the Blood-Brain Barrier
In simple terms: Amyloid-beta is shuttled out of the brain into the blood.
LRP1 and other transporters facilitate the efflux of Aβ across the blood-brain barrier into the periphery, where it can be degraded or cleared by the liver and kidneys.
Enzymatic Degradation
In simple terms: Enzymes chop up amyloid-beta into smaller pieces.
Proteases such as neprilysin and insulin-degrading enzyme degrade Aβ in the brain and periphery, contributing to its clearance.
Peripheral Clearance by Monocytes
In simple terms: Immune cells in the blood help remove amyloid-beta.
Monocytes and macrophages in the periphery take up and degrade Aβ, and their dysfunction is associated with Alzheimer's disease.
Antibody-Mediated Clearance
In simple terms: Therapeutic antibodies help remove amyloid plaques.
Plaque-specific antibodies bind Aβ and promote its clearance by microglia via Fc receptor-mediated phagocytosis, as shown in mouse models.
Key Genes Involved in GO:0097242 amyloid-beta clearance
The following genes and proteins are key players in amyloid-beta clearance, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LRP1 | Receptor for Aβ uptake and transport across BBB | Knockout models show impaired Aβ clearance |
| RAGE | Receptor that mediates Aβ influx into brain | Inhibition reduces Aβ accumulation |
| APOE | Lipid transport, affects Aβ aggregation and clearance | Isoform-specific effects on clearance |
| TREM2 | Microglial receptor for Aβ phagocytosis | Variants increase Alzheimer's risk |
| ABCA1 | Cholesterol efflux, lipidation of APOE | Knockout impairs Aβ clearance |
| Neprilysin (MME) | Aβ-degrading enzyme | Overexpression reduces plaques |
| IDE | Insulin-degrading enzyme, degrades Aβ | Knockout increases Aβ levels |
| APP | Precursor of Aβ | Mutations cause early-onset Alzheimer's |
| BACE1 | Beta-secretase, produces Aβ | Inhibition reduces Aβ production |
| PSEN1 | Gamma-secretase component | Mutations alter Aβ production |
| PSEN2 | Gamma-secretase component | Mutations alter Aβ production |
| CLU | Chaperone, binds Aβ | GWAS risk gene for Alzheimer's |
| CR1 | Complement receptor, immune clearance | GWAS risk gene |
| PICALM | Endocytosis, affects Aβ clearance | GWAS risk gene |
| BIN1 | Membrane remodeling, tau pathology | GWAS risk gene |
| CD33 | Microglial receptor, inhibits phagocytosis | GWAS risk gene |
| MS4A6A | Microglial function | GWAS risk gene |
How Is amyloid-beta clearance Regulated?
Amyloid-beta clearance is regulated at multiple levels, including receptor expression, enzymatic activity, and immune cell function. Inflammatory cytokines can modulate the expression of clearance receptors such as LRP1 and RAGE. Apolipoprotein E (APOE) isoforms differentially affect Aβ clearance, with APOE4 being less efficient than APOE2 or APOE3. Microglial activation state, influenced by TREM2 and CD33, also regulates phagocytic clearance of Aβ. Additionally, peripheral monocyte function and blood-brain barrier integrity impact overall clearance efficiency.
amyloid-beta clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOE | Alzheimer's disease, lipid metabolism | Knock-in mice expressing human APOE isoforms |
| TREM2 | Alzheimer's disease, microglial function | Knockout and knock-in mouse models |
| LRP1 | Alzheimer's disease, BBB transport | Conditional knockout mice |
| APP | Early-onset Alzheimer's disease | Transgenic mice overexpressing mutant APP |
| PSEN1 | Early-onset Alzheimer's disease | Knock-in mice with mutations |
Alzheimer's Disease
Alzheimer's disease is characterized by Aβ plaques and neurofibrillary tangles. Decreased clearance of CNS Aβ is a key pathogenic mechanism, as shown by reduced Aβ clearance rates in patients. Genetic risk factors such as APOE4 and TREM2 variants impair clearance pathways, leading to Aβ accumulation. Therapeutic approaches aimed at enhancing clearance, including anti-Aβ antibodies, have shown promise in clearing plaques.
Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) results from Aβ deposition in blood vessel walls, often due to impaired perivascular clearance. Defects in LRP1-mediated transport across the blood-brain barrier contribute to CAA pathogenesis.
Peripheral Clearance Defects
Monocytes and macrophages in the periphery play a role in Aβ clearance, and their dysfunction is linked to Alzheimer's disease. Peripheral clearance mechanisms are being explored as therapeutic targets.
From amyloid-beta clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate Aβ clearance? | Knockout cell lines and mice |
| Does a point mutation in gene X affect clearance? | Point-mutation knock-in models |
| Can overexpression of gene X enhance clearance? | Overexpression cell lines and transgenic mice |
| How does gene X affect Aβ transport across BBB? | In vitro BBB models with gene editing |
| What is the effect of gene X on microglial phagocytosis? | Primary microglia from knockout mice |
| Can CRISPR screen identify novel clearance regulators? | Genome-wide CRISPR knockout screens in cell models |
How to Study the amyloid-beta clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent Aβ uptake assay | Cellular uptake of Aβ | Screening for clearance enhancers |
| In vivo microdialysis | Aβ levels in brain interstitial fluid | Measuring clearance rates in mice |
| CRISPR knockout screen | Genes affecting Aβ clearance | Identifying novel regulators |
| RNA-seq | Transcriptional changes | Pathway analysis in models |
| Proteomics | Protein expression and modifications | Identifying clearance-related proteins |
| Immunohistochemistry | Aβ plaque load | Evaluating clearance in brain tissue |
| ELISA | Aβ40/Aβ42 levels | Quantifying Aβ in CSF and plasma |
| Live-cell imaging | Real-time Aβ internalization | Visualizing receptor-mediated uptake |
Aβ Clearance Assays
In vitro clearance assays measure the uptake and degradation of fluorescently labeled Aβ by cells, such as microglia or monocytes. These assays can be combined with receptor inhibitors to identify specific pathways.
In Vivo Clearance Measurement
In vivo clearance can be assessed by injecting labeled Aβ into the brain and measuring its disappearance over time using microdialysis or imaging. This approach has been used to demonstrate decreased clearance in Alzheimer's disease patients.
Genetic Manipulation
CRISPR/Cas9 knockout, knock-in, and overexpression models are used to study the role of specific genes in Aβ clearance. These models can be analyzed by biochemical and imaging techniques.
Omics Approaches
Transcriptomics and proteomics can identify global changes in gene expression and protein levels related to Aβ clearance. CRISPR screens enable unbiased discovery of novel regulators.
How CRISPR Can Be Used to Study GO:0097242 amyloid-beta clearance
Knockout
CRISPR knockout of genes such as LRP1, TREM2, or APOE in cell lines and mice can reveal their essential roles in Aβ clearance. Knockout models often show impaired Aβ uptake or increased plaque burden.
Point Mutation
Point mutations can be introduced to model human genetic variants, such as TREM2 R47H, to study their impact on Aβ clearance. These models help dissect the functional consequences of specific alleles.
Knock-in
Knock-in of human APOE isoforms or APP mutations into mouse models allows study of human-relevant clearance mechanisms. These models are valuable for preclinical drug testing.
Overexpression
Overexpression of clearance-related genes, such as Neprilysin or LRP1, can enhance Aβ clearance and reduce plaque load in mouse models. Overexpression models are used to test therapeutic potential.
How EDITGENE Supports amyloid-beta clearance Research
Researchers studying amyloid-beta clearance-related genes often need to determine whether a candidate gene is causally involved in Aβ removal or merely a biomarker. CRISPR-based models provide a robust way to establish causality and dissect molecular mechanisms.
Contact EDITGENE today to design your custom CRISPR model for amyloid-beta clearance research.
Frequently Asked Questions About amyloid-beta clearance
What is amyloid-beta clearance?
Amyloid-beta clearance (GO:0097242) is the process by which amyloid-beta is removed from extracellular brain regions via cell surface receptors.
What genes are involved in amyloid-beta clearance?
Key genes include LRP1, RAGE, APOE, TREM2, ABCA1, Neprilysin, IDE, and others.
How is amyloid-beta cleared from the brain?
It is cleared by receptor-mediated uptake, transport across the blood-brain barrier, enzymatic degradation, and peripheral immune cells.
Why is amyloid-beta clearance important in Alzheimer's disease?
Impaired clearance leads to Aβ accumulation, a hallmark of Alzheimer's disease.
What are the mechanisms of amyloid-beta clearance?
Mechanisms include receptor-mediated endocytosis, efflux across the blood-brain barrier, enzymatic degradation, and antibody-mediated phagocytosis.
Can CRISPR be used to study amyloid-beta clearance?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to study genes involved in Aβ clearance.
What cell types are involved in amyloid-beta clearance?
Neurons, microglia, astrocytes, endothelial cells, and peripheral monocytes participate in Aβ clearance.
How is amyloid-beta clearance measured?
It can be measured by in vitro uptake assays, in vivo microdialysis, ELISA for Aβ levels, and imaging techniques.
What is the role of APOE in amyloid-beta clearance?
APOE isoforms differentially affect Aβ aggregation and clearance, with APOE4 being less efficient.
Are there therapies targeting amyloid-beta clearance?
Yes, anti-Aβ antibodies such as plaque-specific antibodies enhance clearance and reduce plaques in mouse models.
Conclusion
Amyloid-beta clearance (GO:0097242) is a fundamental biological process that prevents Aβ accumulation in the brain. Its impairment is a key driver of Alzheimer's disease, and understanding its molecular mechanisms offers therapeutic opportunities. CRISPR-based models and screening approaches are powerful tools to dissect the genetic regulation of Aβ clearance and to identify new drug targets.
References
- 1. Chen GF et al.. 2017. Amyloid beta: structure, biology and structure-based therapeutic development.. Acta Pharmacol Sin 38(9):1205-1235 PMID: 28713158
- 2. Mawuenyega KG et al.. 2010. Decreased clearance of CNS beta-amyloid in Alzheimer's disease.. Science 330(6012):1774 PMID: 21148344
- 3. Guo H et al.. 2019. Monocytes in the Peripheral Clearance of Amyloid-β and Alzheimer's Disease.. J Alzheimers Dis 68(4):1391-1400 PMID: 30958361
- 4. Tsoy A et al.. 2024. Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer's Disease.. Int J Mol Sci 25(20) PMID: 39456746
- 5. Ueno M et al.. 2014. Clearance of beta-amyloid in the brain.. Curr Med Chem 21(35):4085-90 PMID: 25312211
- 6. Xin SH et al.. 2018. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.. Neurotox Res 34(3):733-748 PMID: 29626319
- 7. Hardy J et al.. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.. Science 297(5580):353-6 PMID: 12130773
- 8. Demattos RB et al.. 2012. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.. Neuron 76(5):908-20 PMID: 23217740
